A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults
Laroprovstat/ezetimibe FCDP: Laroprovstat/ezetimibe will be administered orally.
Laroprovstat STP: Laroprovstat will be administered orally.
Ezetimibe STP: Ezetimibe will be administered orally.
Laroprovstat/ezetimibe FCDP-slow variant: Laroprovstat/ezetimibe slow variant will be administered orally
Study summary
The purpose of this study is to assess how well laroprovstat and ezetimibe combined in a single tablet to be taken by mouth works and what the body does to the drug (pharmacokinetics) compared with laroprovstat and ezetimibe individual tablets to be taken by mouth (relative bioavailability) as well as to see if there is any effect of eating compared to fasting (food effect) in healthy adults.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Healthy male and female participants aged 18 to 55 years at the time of signing consent.
* All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.
* Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.
* Have a Body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.
Exclusion Criteria:
* History of any clinically important disease or disorder.
* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class to laroprovstat or ezetimibe.
* Treatment with any lipid lowering therapy or laroprovstat within the 3 months prior to the Screening Visit.
* Treatment with drugs for reduction or inhibition of Proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit or inclisiran at any time.
Primary outcome measure(s)
Area under concentration-time curve from time 0 to infinity (AUCinf) — Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days) To evaluate the relative bioavailability between the FCDPs and the STPs of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe.
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) — Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days) To evaluate the relative bioavailability between the FCDPs and the STPs of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe.
Maximum observed drug concentration (Cmax) — Day 1 to 11 of Treatment Periods 1, 2, 3, and 4 (each treatment period is 11 days) To evaluate the relative bioavailability between the FCDPs and the STPs of laroprovstat, ezetimibe (unconjugated), ezetimibe-glucuronide, and total ezetimibe.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.